A-share Selected Announcements | Total amount reaches 4.2 billion yuan, Neusoft Corporation (600718.SH) wins a major contract for intelligent cockpit project from a well-known car enterprise.

Focus today 1. Neusoft Corporation: Received a targeted notification from a well-known large domestic car manufacturer for intelligent cockpit domain controller amounting to 4.2 billion yuan. Neusoft Corporation announced that it has recently received a targeted notification from a well-known large domestic car manufacturer, selecting Neusoft as its designated supplier to provide intelligent cockpit domain controllers. According to the car manufacturer's plan, the above products will be used in multiple vehicle models scheduled for mass production and release between 2026 and 2027, with an estimated lifecycle of about 6 years. During the lifecycle of the aforementioned vehicle models, the company is expected to provide intelligent cockpit domain controllers amounting to around 4.2 billion yuan. The intelligent cockpit domain controller products provided to the car manufacturer in this project will be based on the Qualcomm platform and will deeply integrate AI computing power with multimodal large model technology to build a comprehensive perception and inference capability covering all scenarios, enhancing interaction experience and efficient multitasking processing capabilities. Neusoft has maintained a long-term good cooperation relationship with the car manufacturer, and its intelligent cockpit, intelligent communication, and other series of products have been successfully applied to various mainstream vehicle models of the car manufacturer. This targeted project is a further deepening of the long-term cooperation between the two parties, and it is also a continuous recognition by the car manufacturer of Neusoft's comprehensive strength in automotive intelligence core products and technologies, beneficial for further consolidating the company's leading advantages and continuously enhancing its core competitiveness and market share. 2. Beijing YanDong MicroElectronic: Shareholders National Integrated Circuit Fund and Jingguorui plan to collectively reduce their shareholdings by no more than 2.5% of the company's shares. Beijing YanDong MicroElectronic announced that its shareholder, the National Integrated Circuit Fund holding more than 5% of the shares, plans to reduce the company's shares by no more than 21.4143 million shares, accounting for no more than 1.5% of the total share capital, through block trading or centralized bidding for its own operational needs. The reduction period is from December 11, 2025, to March 11, 2026. Shareholder Jingguorui also plans to reduce the company's shares by no more than 14.2762 million shares, accounting for no more than 1% of the total share capital, through block trading or centralized bidding for its own operational needs during the same period. 3. Cowealth Medical China: Completion of verification, resumption of trading of company's shares from November 20. Cowealth Medical China announced that in the recent period, the company conducted verification on related matters concerning abnormal fluctuations and severe abnormal fluctuations in stock trading. Given that the related verification work has been completed, upon application to the Shanghai Stock Exchange, the company's shares will resume trading from November 20. Through self-examination, the company's daily operational activities are normal, and there have been no significant changes in the internal and external operational environment of the company. As of the disclosure date of the announcement, apart from the information publicly disclosed in designated media outlets, there are no significant matters affecting the abnormal fluctuations in the company's stock trading prices; there is no other significant information related to the company that should be disclosed but has not been disclosed. 4. Sichuan Biokin Pharmaceutical: Bank of China Sichuan Branch commits to providing comprehensive credit support totaling no less than 8 billion yuan in equivalent RMB. Sichuan Biokin Pharmaceutical announced that the company has signed a "Strategic Cooperation Agreement" with the Bank of China Sichuan Branch. The Bank of China Sichuan Branch, under the premise of complying with relevant national laws and regulations and credit approval conditions, has pledged to provide comprehensive credit support to Sichuan Biokin Pharmaceutical totaling no less than 8 billion yuan in equivalent RMB. The two parties will also engage in deep cooperation in areas such as domestic and international capital market operations, cross-border finance, and international business cooperation. The agreement is valid for five years and will automatically be extended after expiry. The signing of this strategic cooperation agreement is conducive to the company accelerating its strategic layout in the global biopharmaceutical frontier field, consolidating its global leading advantages in areas such as antibody-drug conjugates (ADCs) and multispecific antibodies, and capturing new opportunities for the development of the global biopharmaceutical industry, achieving mutual benefit, and common development between the two parties. 5. Qingdao Baheal Medical INC.: Zap Therapeutic plans to inject $4.9 million into Baiyang Sapp, assisting the rapid introduction of the ZAP-X Mars Boat Radio Surgery Siasun Robot & Automation into clinical scenarios. Qingdao Baheal Medical INC. announced that its wholly-owned subsidiary, Baiyang Health Industry International Trade Co., Ltd.'s wholly-owned subsidiary, Hebei Baiyang Sapp Medical Equipment Technology Co., Ltd., plans to raise $4.9 million from Zap Therapeutic. After the capital injection, Baiyang Sapp's registered capital will increase to USD 10 million, with Baiyang Health's shareholding decreasing to 51%. To expand the company's product layout in the innovative medical device field, since July 2024, the company has gradually invested in Zap Medical System, Ltd., and has conducted a series of exclusive commercial cooperation, manufacturing services, etc., for its core product ZAP-X Mars Boat Radio Surgery Siasun Robot & Automation. The capital injection from Zap Therapeutic to Baiyang Sapp will fully integrate the resources advantages of both parties in terms of funds, technology, market channels, etc., to promote the localization production of ZAP-X and help accelerate its rapid introduction into clinical scenarios. 6. Jiangxi Ganyue Expressway: The actual controller will be changed from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission. Jiangxi Ganyue Expressway announced that the company received a notification letter from the Provincial Transportation Investment Group, and with the approval of the Jiangxi Provincial Government, the Provincial Department of Transportation has transferred its 90% equity in the Provincial Transportation Investment Group, at no cost, to Jiangxi National Control, and then transferred to the Provincial State-owned Assets Supervision and Administration Commission. After the completion of this major event, the Provincial State-owned Assets Supervision and Administration Commission will directly hold 90% of the equity of the Provincial Transportation Investment Group, while the Provincial Transportation Investment Group's shareholding in the company remains unchanged. The controlling shareholder of the company is still the Provincial Transportation Investment Group, and the actual controller of the company has changed from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission. 7. Huizhou Desay SV Automotive: Officially launched an AI computing terminal for the Siasun Robot & Automation field recently, applying vehicle-level redundant design of the auxiliary driving domain controller to Siasun Robot & Automation scenarios. Huizhou Desay SV Automotive released its investor relations activity record, stating that the company has secured new project orders from several internationally renowned car manufacturers and has set up production bases in Europe. The company has partnered with several well-known Siasun Robot & Automation enterprises, and recently officially launched the Siasun Robot & Automation intelligent base AI Cube, an AI computing terminal for the Siasun Robot & Automation field. The vehicle-level redundant design of the auxiliary driving domain controller has been applied to Siasun Robot & Automation scenarios, aiming for "zero defects', significantly improving the durability and reliability of key components of Siasun Robot & Automation, effectively enhancing its intelligence level in complex environments, possessing universal capabilities across scenarios, achieving comprehensive adaptation from industry to home. Additionally, by providing technical services such as model rapid adaptation deployment, model optimization, and computing acceleration optimization, customers are helped to enhance the speed of large model computing inference. 8. Zhejiang Hisun Pharmaceutical: Subsidiary plans to collaborate with East China Institute on the Biogenic Synthesis Heparin project to promote the development of synthetic biology industry. Zhejiang Hisun Pharmaceutical announced that its holding subsidiary Haizhengdongbao plans to establish a wholly-owned subsidiary in Jiaojiang District, Taizhou City with its own funds of 100 million yuan and invest in the construction of a pet prescription food project. The project is located in Jiaojiang District, Taizhou City, Zhejiang Province, with an investment of 200 million yuan, of which 100 million yuan will be contributed by shareholders. The project will be implemented in two phases, with the first phase having a construction period of 24 months, and the second phase expanding the production capacity and improving supporting facilities. After reaching production, the project is expected to add an annual production capacity of 10,000 tons of pet prescription food. To further supplement the company's product coverage in the field of synthetic biology and promote the development of the synthetic biology industry, the wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., plans to sign a "Technical Cooperation and Development Contract" with East China Institute for the development and industrialization of bioengineered heparin drugs using biogenic synthesis. The total contract amount for the project is not more than 120 million yuan. 9. Hua Hong Semiconductor: NORFLASH growth rate in the third quarter faster than the overall market. Flash memory business is expected to have strong growth in the coming quarters or even years. Hua Hong Semiconductor announced in its investor relations activity record that the company's storage business focuses on NORFLASH, a segment market within the flash memory business. NORFLASH is divided into two parts, standalone flash products, and MCU. The company witnessed strong performance in the flash memory business in the third quarter. While the overall NORFLASH market showed steady growth, the company's growth rate in the third quarter was clearly faster than the overall market. This may be more related to the company's own situation, as its 55nm NORFLASH has entered mass production in the past few quarters, and its 55nm MCU is also entering mass production. Next year or the year after, the company will launch 40nm products, which will provide another boost. Overall, the company indeed sees strong growth in the flash memory business in the coming quarters or even years, mainly driven by the company's transition to new technology nodes. The dynamics of other storage businesses may differ. In terms of capacity expansion, Wuxi Plant 9 continues to ramp up, with capacity expected to be in place by the third quarter of next year. In terms of product portfolio optimization, with technological node advancements, our key technologies will become better and more competitive. Regarding flash-related technologies, with the launch of our 55nm products and the upcoming 40nm products next year, we will be in a stronger position in the flash memory business field. 10. Chengdu Sheng Nuo Biotec: The raw material drug of Velanatide has received a notice of approval for listing application, used for the treatment of type 2 diabetes and obesity. Chengdu Sheng Nuo Biotec announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biotec Pharmaceutical Co., Ltd., has received the "Notice of Approval for Application for the Listing of Chemical Raw Materials" from the National Medical Products Administration regarding the raw material drug of Velanatide. Velanatide is a polyethylene glycol (PEG)-modified exenatide used to treat type 2 diabetes and obesity. The approval letter is a demonstration of the company's comprehensive strength in research and development, production, and quality management systems, which has a positive effect on the company's business development. Stock action risk warnings: Shenzhen Dawei Innovation Technology, which has risen for two consecutive days: The Hunan Chenzhou Lithium Battery New Energy Industry project is currently processing the exploration and transfer procedures. Repurchase & decrease in holdings: 1. Apeloa Pharmaceutical: Plans to repurchase shares worth 180 million to 360 million yuan for incentive programs. 2. Guangdong Haid Group: First-time share buyback of 7.9941 million yuan through centralized bidding. 3. Cosmos Group: Completed a buyback of shares worth 29.9955 million yuan, accounting for 1.31% of the total share capital. 4. Warom Technology Incorporated: First-time share buyback through centralized bidding. 5. Kingchem: Shareholders Qulu Investment, Qingsong Investment, and Lanzhou Fund plan to collectively reduce their holdings by no more than 5.94%. 6. Zhejiang KangLongDa Special Protection Technology: Shareholder Helin Fund plans to reduce its holdings by no more than 3%. 7. Zhejiang Haiyan Power System Resources Environmental Technology: Shareholder Huilian No. 2 plans to reduce its holdings by no more than 2.0303%. 8. HPGC Renmintongtai Pharmaceutical Corporation: Controlling shareholder Harbin Pharmaceutical Group plans to reduce its holdings by no more than 1%. Large transactions: 1. Beijing Hanjian Heshan Pipeline: Won a 3.88 billion yuan water supply project pipe procurement project. 2. Zhejiang Dafeng Industry: Won a 1.65 billion yuan project, accounting for nearly 9% of last year's revenue. 3. Jiangsu Jiangnan Water: Signed a 3.68 billion yuan contract.